论文部分内容阅读
对胸外科１９７９年～１９９１年底经手术切除的１６５例Ⅲ期小细胞肺癌（ＳＣＩＣ）的治疗效果进行分析，并将其中的８７例综合治疗病例与７８例单纯手术病例进行对比讨论。同时，就综合治疗组中术前化学治疗（化疗）和（或）放射治疗（放疗）对预后的影响做了观察。全组５年生存率占１６．６％。ＴＮＭ分期５年生存率Ⅲａ期达２０．４％，Ⅲｂ期为０。综合治疗５年生存率占２２．８％，单纯手术５年生存率占７．９％。结果显示：Ⅲａ期ＳＣＬＣ综合治疗优于单纯手术治疗；综合治疗组中Ｎ＿２术前化疗和（或）放疗病例较术后化疗和（或）放疗病例预后变差；手术适应证应限于Ⅲａ期病例。
The therapeutic effect of 165 cases of stage III small cell lung cancer (SCIC) surgically resected from 1979 to 1991 at the end of thoracic surgery was analyzed, and 87 cases of comprehensive treatment cases were compared with 78 cases of simple surgical cases. At the same time, the effect of preoperative chemotherapy (chemotherapy) and/or radiation therapy (radiotherapy) on the prognosis of the comprehensive treatment group was observed. The 5-year survival rate in the whole group was 16.6%. The 5-year survival rate of TNM stage IIIa was 20.4%, and stage IIIb was 0. The 5-year survival rate for comprehensive treatment accounted for 22.8%, and the 5-year survival rate for only surgery was 7.9%. The results showed that stage IIIa SCLC combined therapy was superior to surgery alone; the N 2 preoperative chemotherapy and (or) radiotherapy in the combined treatment group had worse prognosis than the postoperative chemotherapy and (or) radiotherapy; the surgical indication should be limited to stage IIIa cases .